KP Tissue (TSE:KPT - Get Free Report) had its target price hoisted by investment analysts at Desjardins from C$9.50 to C$10.00 in a research report issued to clients and investors on Thursday,BayStreet.CA reports. The brokerage presently has a "hold" rating on the stock. Desjardins' price objective suggests a potential upside of 4.71% from the stock's previous close.
Other research analysts have also issued research reports about the company. TD Securities boosted their target price on KP Tissue from C$8.00 to C$9.00 and gave the company a "hold" rating in a report on Thursday, May 22nd. National Bankshares boosted their target price on KP Tissue from C$8.50 to C$9.50 and gave the company a "sector perform" rating in a report on Thursday, May 22nd.
Get Our Latest Stock Report on KPT
KP Tissue Stock Performance
TSE KPT traded up C$0.05 on Thursday, reaching C$9.55. The stock had a trading volume of 12,300 shares, compared to its average volume of 16,224. KP Tissue has a 12-month low of C$7.54 and a 12-month high of C$9.64. The business's 50-day moving average price is C$9.12 and its 200 day moving average price is C$8.48. The stock has a market cap of C$95.44 million, a P/E ratio of 14.95, a price-to-earnings-growth ratio of -0.88 and a beta of 0.37.
KP Tissue Company Profile
(
Get Free Report)
KP Tissue Inc, through its interest in Kruger Products L.P., produces, distributes, markets, and sells a range of disposable tissue products in Canada and the United States. The company operates through two segments, Consumer and Away-From-Home. It offers bathroom and facial tissues, paper towels, and napkins.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider KP Tissue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KP Tissue wasn't on the list.
While KP Tissue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.